Genmab's Scores A 'Hat Trick' And Cruises 60% In A Month
Genmab's stock rose 60% in October, driven by positive results from its cancer treatments Epkinly and Rina-S, according to CEO Jan van de Winkel. Epkinly outperformed standard care in lymphoma patients, while Rina-S succeeded in a late-stage study.
How this was made
The 30-second read
Why it matters
The dual trial successes constitute a material catalyst, explaining the 60% price jump and likely attracting further investor interest.
Market read
The news directly explains the sharp stock rally and may influence biotech sector sentiment.
What to watch
Upcoming FDA review timeline and competition from other lymphoma therapies.
Background
Genmab announced that its drug Epkinly outperformed standard of care in lymphoma patients and its ADC Rina‑S succeeded in a final‑phase study.
Ticker impact
Genmab stock surged 60% after reporting positive Phase III trial results for Epkinly and Rina‑S.
upward pressure as investors price in the successful trial outcomes
Breakthrough oncology results are material news for a biotech and often trigger sustained price gains.
Market effects
May boost sentiment in the oncology biotech sector.
Positive for European biotech markets where Genmab is listed.
Limited to biotech investors; no broad market effect.
Counterpoint
Skeptics may question durability of trial data and potential regulatory hurdles.
Key entities
- companyGenmab
Biotech firm developing oncology therapies.
- productEpkinly
Genmab's lymphoma drug showing positive trial results.
- productRina‑S
Genmab's antibody‑drug conjugate succeeding in final‑phase study.

